Introduction {#S1}
============

Tuberculosis (TB) remains a major cause of death worldwide and the leading cause by a single infectious agent ([@B43]). Even though the disease can be cured and managed by several multidrug regimens, the emergence of multidrug-resistant (MDR) TB is proving to be a major challenge for complete eradication of the disease. Worldwide, MDR TB constitutes 3.5% of new TB cases and 18% of previously treated cases ([@B43]). To overcome these challenges and to better counter resistance in *Mycobacterium tuberculosis* (*Mtb*), understanding the mechanisms and deciphering the pathways majorly responsible for generating resistance are greatly required.

Isoniazid (INH), in combination with rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA), forms the first-line therapy for TB. Cycloserine, ethionamide (ETH), and amikacin/capreomycin are used as second-line drugs^[1](#footnote1){ref-type="fn"}^. INH was first used as an anti-TB drug in 1952 and shortly the first INH-resistant *Mtb* (INHr) clinical isolates were reported ([@B6]; [@B11]; [@B27]). INH and ETH are prodrugs that are converted into their active forms by proteins encoded by *katG* (catalase peroxidase KatG) and *ethA* (monooxygenase EthA), respectively ([@B19]; [@B18]; [@B4]; [@B10]; [@B41]; [@B12]). Although *katG* and *inhA* (encoding an NADPH-dependent enoyl-ACP reductase) are the main genes involved in INH resistance, clinical isolates with mutations in the *ndh* gene have been identified in INH-resistant *Mtb* strains ([@B22]). While in the study by [@B22], INH resistance mutations were observed only in the *ndh* gene, in other studies, *ndh* mutations occur simultaneously with mutations in other genes ([@B16]; [@B7]). The role of the *ndh* gene mutations in INH and ETH co-resistance in *Mycobacterium smegmatis* (*Msmeg*) and *Mycobacterium bovis* (*Mbovis*) has been shown ([@B42]), while the role of *ndh* in conferring resistance in *Mtb* is yet to be determined. The gene *ndh* encodes the type II NADH dehydrogenase and its ortholog in *Escherichia coli* (*E. coli*) has been characterized. In *E. coli*, it exists in a monomeric state bound to the membrane, where it oxidizes NADH, reduces quinone, and catalyzes the transfer of electrons from reduced flavin to quinone ([@B17]; [@B26]; [@B44]; [@B14]; [@B20]). In *Msmeg*, mutations in *ndh* lead to an increase in NADH cellular concentration and inhibition of INH-NAD and ETH-NAD adducts formation ([@B42]).

Xenobiotic response element (XRE) family of transcription factors are one of the most frequently occurring families of regulators in bacteria. Among the well-studied members of the XRE family are the lambda and Cro repressors, from lambda bacteriophage, and the prophage repressor Xre from *Bacillus subtilis*. The XRE family of regulators share a conserved N-terminal helix-turn-helix (HTH) DNA binding domain, while the C-terminal regulatory region is highly variable. The XRE family of regulators control diverse metabolic functions; e.g., SinR regulates developmental process in *B. subtilis* ([@B13]), ClgR regulates *Streptomyces* growth and controls Clp proteolytic complex ([@B5]), PuuR regulates putrescine utilization pathway in *E. coli* K-12 ([@B31]), and BzdR is involved in the anaerobic catabolism of benzoate in the denitrifying *Azoarcus* sp. strain CIB ([@B3]). There are seven members of the XRE family of transcription regulators in *Mtb*: Rv0023, Rv0465c, Rv0474, Rv1129, Rv2017, Rv2021, and EspR (*Rv3849*). Except for EspR, which positively regulates the ESX-1 protein secretion system, the principal virulence determinant of *Mtb* ([@B34]), the remaining XRE transcription regulators in *Mtb* are uncharacterized.

Rv0023 is a regulator from the XRE family of transcriptional regulators, known to induce 488 genes and repress 404 genes ([@B35]). Rv0023 regulon is enriched for the regulation of NAD reductases ([@B35]). *Rv0023* is transcribed in an operon together with *Rv0024*, a gene that codes for an NLPC/p60 family protein and is transcribed divergently from *whiB5*, belonging to the WhiB family of transcriptional regulators. The *whiB5* gene product is a positive regulator of transcription and contributes to *Mtb* virulence and reactivation ([@B9]). At present, very little is known about Rv0023 functions and its effect on *Mtb* physiology.

Here, we studied the effects of Rv0023 overexpression in *Msmeg.* The results show that ectopic expression of Rv0023 confers enhanced INH and ETH tolerance in *Msmeg.* Rv0023 ectopic expression downregulates the expression of the *ndh* gene and increases NADH/NAD^+^ levels, which are known to be mediators of INH and ETH resistance in *Msmeg* ([@B28]; [@B42]). We further studied the regulation of the *whiB5-Rv0023* locus and identified Rv0023 as a negative regulator of *whiB5*. We have characterized its binding site and identified the promoters of *Rv0023* and *whiB5*.

Materials and Methods {#S2}
=====================

Bacterial Strains and Growth Condition {#S2.SS1}
--------------------------------------

A complete list of strains used in this study is mentioned in [Table 1](#T1){ref-type="table"}. Cloning and plasmid propagation were done using *E. coli* strain DH5α. For protein expression, *E. coli* BL21 (DE3) was used. Both strains were grown in Luria Bertani (LB) medium at 37°C. *Mbovis* BCG Pasteur 1173P2, *Msmeg* mc^2^155, and the recombinant strains were grown in Middlebrook 7H9 (Himedia) broth supplemented with 10% OADC (oleic albumin dextrose catalase) (Himedia), 0.2% glycerol, and 0.05% Tween80 (20% stock) or on 7H10 agar without Tween80 at 37°C. Kanamycin (50 μg/ml) (Sigma-Aldrich), ampicillin (100 μg/ml) (Sigma-Aldrich), and hygromycin (50 μg/ml) (Invitrogen) were used as and when required.

###### 

List of strains used in this study.

  Strain                      Chromosomal genotype                                                                                                         Source
  --------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------
  *E. coli* DH5α              F-- Φ80*lac*ZΔM15 Δ(*lac*ZYA-*arg*F) U169 *rec*A1 *end*A1 *hsd*R17 (rK−, mK+) *pho*A *sup*E44 λ-- *thi*-1 *gyr*A96 *rel*A1   Lab repository
  *E. coli* BL21 (DE3)        fhuA2 \[lon\] ompT gal (λ DE3) \[dcm\] ΔhsdS λ DE3 = λ sBamHIo Δ*Eco*RI-B int:(lacI:PlacUV5:T7 gene1) i21 Δnin5              Lab repository
  *M. smegmatis* mc^2^155                                                                                                                                  Lab repository
  *Msmeg*pVV16                *M. smegmatis* mc^2^155 harboring pVV16 plasmid                                                                              This study
  *Msmeg*pVV0023              *M. smegmatis* mc^2^155 harboring pVV0023 plasmid                                                                            This study
  *Msmeg*pEJ*whiB5*WT         *M. smegmatis* mc^2^155 harboring pEJwhiB5 plasmid                                                                           This study
  *Msmeg*pEJ*whiB5*MUT        *M. smegmatis* mc^2^155 harboring pEJwhib5MUT plasmid                                                                        This study
  *Msmeg*pEJ0023WT            *M. smegmatis* mc^2^155 harboring pEJ0023 plasmid                                                                            This study
  *Msmeg*pEJ0023MUT           *M. smegmatis* mc^2^155 harboring pEJ0023MUT plasmid                                                                         This study
  *Msmeg*pEJ*whiB5*-pVV16     *M. smegmatis* mc^2^155 harboring pEJ*whiB5* and pVV16 plasmids                                                              This study
  *Msmeg*pEJ*whiB5-*pVV0023   *M. smegmatis* mc^2^155 harboring pEJ*whiB5* and pVV0023 plasmids                                                            This study
  *Msmeg*pEJ0023-pVV16        *M. smegmatis* mc^2^155 harboring pEJ*0023* and pVV16 plasmids                                                               This study
  *Msmeg*pEJ0023-pVV0023      *M. smegmatis* mc^2^155 harboring pEJ*0023* and pVV0023 plasmids                                                             This study
  *Msmeg*pVV0494              *M. smegmatis* mc^2^155 harboring pVV0494 plasmid                                                                            [@B45]

Plasmids and DNA Manipulation {#S2.SS2}
-----------------------------

Cloning, genomic, and plasmid DNA isolations were done as per standard molecular biology procedures ([@B36]). The plasmids and primers used in this study are listed in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, respectively. Overlapping extension PCR was performed to generate site-directed mutations for promoter and critical residues studies. Sequences of all clones generated were confirmed by Sanger sequencing.

###### 

List of plasmids used in this study.

  Plasmid         Features                                                                      Source/reference
  --------------- ----------------------------------------------------------------------------- ------------------
  pET23a0023      pET21b carrying Rv0023 gene                                                   This study
  pEJ414          km^r^ and lacZ reporter vector                                                [@B33]
  pEJ0023WT       pEJ414 carrying 400bp upstream and 50bp downstream of *Rv0023* start codon    This study
  pEJ0023MUT      Derivative of pEJ0023 where TCATAG is mutated to CCAGAG                       This study
  pEJ*whiB5*WT    pEJ414 carrying 250 bp upstream and 50 bp downstream of *whiB5* start codon   This study
  pEJ*whiB5*MUT   Derivative of pEJ*whiB5* where ATACGCTT is mutated to GCACGCGG                This study
  pVV16           Hsp60 promoter, Km^r^ and Hyg^r^                                              [@B21]
  pVV0023         pVV16 carrying *Rv0023* gene                                                  This study
  pVV0494         pVV16 carrying *Rv0494* gene                                                  [@B45]

###### 

List of primers used for cloning.

  Clone name      Primer           Sequence                                                                 Restriction site
  --------------- ---------------- ------------------------------------------------------------------------ ------------------
  pET0023         0023FP           GGGAATTC[CATATG]{.ul}AGCCGTGAGTCGGCCGGCGCGGCC                            *Nde*I
                  0023RP           CCG[CTCGAG]{.ul}CTGCTGCCCCTCATCCGCGTCGTG                                 Pst1
  pEJ0023WT       UP0023FP         CTAG[TCTAGA]{.ul}AGCTGTTCGCGCTTTCGGTACTGGC                               *Xba*I
                  UP0023RP         CCC[AAGCTT]{.ul}CGCGAAGTGCGCGAATGGCCGC                                   *Hin*dIII
  pEJ0023MUT      UP0023SDMFP      TGGCC[GACCGC]{.ul}**[G]{.ul}**[CA]{.ul}**[GC]{.ul}**[GGCGCGTGCCT]{.ul}   *Xba*I
                  UP0023SDMRP      AGGCACGCGCC**GC**TG**C**GCGGTCGGCCA                                      *Hin*dIII
  pEJ*whiB5*WT    UP*whiB5*FP      CTAG[TCTAGA]{.ul}GAGCTGTGCTTCGGCGTAGC                                    *Xba*I
                  UP*whiB5*RP      CCC[AAGCTT]{.ul}ATCGGGGTACCCGAACC                                        *Hin*dIII
  pEJ*whiB5*MUT   UP*whiB5*SDMFP   CACAGACAT**GC**ACGC**GG**TTGCCTATGTTTCGTTCAACAA                          *Xba*I
                                   GGAGGCCGGCACAAGCTTGGG                                                    
                  UP*whiB5*SDMRP   CCCAAGCTTGTGCCGGCCTCCTTGTTGAACGAAACATAGG                                 *Hin*dIII
                                   CAA**CC**GCGT**GC**ATGTCTGTG                                             
  pVV0023         pvv0023FP        GGGAATTC[CATATG]{.ul}AGCCGTGAGTCGGCCGGCGCGGCC                            *Nde*I
                  pvv0023RP        AAAA[CTGCAG]{.ul}CTGCTGCCCCTCATCCGCGTCGTG                                *Hin*dIII
  pEJUF1          UF1FP            GGGCCTGAGCTATCTGGAGCGCG                                                  
                  UF1RP            CGCGCTCCAGATAGCTCAGGCCC                                                  
  pEJUF2          UF2FP            CTGTGCTTTTGTGTGGCTTGCG                                                   
                  UF2RP            CGCAAGCCACACAAAAGCACAG                                                   

Restriction site in the primer was underlined. The point mutations incorporated in SDM primers were highlighted in bold.

Protein Expression and Purification {#S2.SS3}
-----------------------------------

pET23a-0023 plasmid containing *Rv0023* ORF was used to transform *E. coli* BL21 (DE3) strain. Cells were grown in LB broth at 37°C till mid-log phase, and then 1 mM IPTG (isopropyl 1-thio-β-D-galactopyranoside) was added to induce the expression of protein. Cells were grown for another 4 h at 37°C, after which cells were harvested and purified using Ni-NTA affinity chromatography as described earlier ([@B46]). The purity of recombinant protein was analyzed by 12% SDS-PAGE and protein concentration was measured by Bradford assay.

β-Galactosidase Assay {#S2.SS4}
---------------------

*Mycobacterium smegmatis* mc^2^155 strain was transformed with various constructs as required and grown in 7H9 media. The cultures were grown to mid-log phase and β-galactosidase activity was measured in Miller Units (MU) and all experiments were done in triplicate ([@B29]).

Electrophoretic Mobility Shift Assay {#S2.SS5}
------------------------------------

To verify the interaction between Rv0023 and the upstream region of *whiB5*, electrophoretic mobility shift assay (EMSA) was performed. The 500-bp upstream region and the 50-bp downstream region of *whiB5* were PCR amplified and labeled with γ-^32^P ATP (3000 Ci mmol^--1^) using T4 polynucleotide kinase as per manufacturer's instructions (New England Biolabs). Labeled DNA was purified using nucleotide purification kit (Qiagen). Purified labeled DNA was then incubated with increasing concentrations of recombinant Rv0023 protein in an EMSA reaction buffer (25 mM HEPES, pH 7.9, 0.1 mM EDTA, 10 mM MgCl~2~, 20 mM KCl, and 5% glycerol) with 50 ng/μl poly(dI--dC) as a non-specific DNA competitor. The protein--DNA complex was incubated for 45 min and was resolved on a 6% non-denaturing polyacrylamide gel in 0.5 × tris-borate (TBE) buffer. The gel was run for 3--4 h to allow sufficient resolution of protein--DNA complex.

Electrophoretic mobility shift assay with commercially synthesized overlapping oligonucleotide and motifs was performed to identify the exact binding region of Rv0023.

Primer Extension {#S2.SS6}
----------------

To map the (+1) transcription start site (TSS), primer extension was performed as described earlier and in Cold Spring Harbor protocols ([@B8]; [@B1]). As the ORFs and intergenic region of *whiB5-Rv0023* locus are 100% conserved between *Mtb* and *Mbovis*, we used *Mbovis* RNA for primer extension studies. RNA was isolated with the Qiagen RNeasy kit as per manufacturer's instructions. SuperScript III reverse transcriptase (Invitrogen) was used to transcribe cDNA from total RNA (10--15 μg) using 5′-end labeled γ-^32*P*^ ATP primers ([Table 4](#T4){ref-type="table"}). Primer extension products were resolved on 6% polyacrylamide/8 M urea gel in TBE buffer. The size of primer extension product was determined by generating a dideoxy sequencing ladder using pUC19 plasmid as template and M13 universal primer (USB; 70140 KT).

###### 

List of primers used in primer extension.

  Primer    Sequence
  --------- -------------------------
  0023PE1   CTCACGGCTCACCGCACGCTCCG
  0023PE2   CGCGAAGTGCGCGAATGGCCGC

Stress Assay {#S2.SS7}
------------

To check the sensitivity of *Msmeg* toward various stress conditions, *Msmeg*WT, *Msmeg*pVV16, and *Msmeg*pVV0023 cells were grown in complete 7H9 media (supplemented with 10% OADC, 0.2% glycerol, and 0.05% Tween80) at 37°C overnight. Then, the cells were centrifuged and washed with PBS. The cells were then suspended in 7H9 media and the cell concentration was adjusted to 0.02 OD at 600 nm. The sensitivity of bacterial cultures toward 0.1% SDS (Sigma Aldrich) and 5 mM hydrogen peroxide (Merck) was measured at 37°C for 6 h. Sensitivity to 250 μg/ml lysozyme (Sigma Aldrich) was measured at 37°C for 24 h. Susceptibility of *Msmeg* toward the antibiotics (Sigma Aldrich) INH (10 μg/ml, MIC of 5 μg/ml), RIF (10 μg/ml, MIC of 1 μg/ml), and ETH (2.5 μg/ml, MIC of 10 μg/ml) was determined at 37°C for 24 h. For determining CFU numbers for each stress condition and antibiotics, the cells were serially diluted (10-fold) and plated onto 7H10 agar plates.

Further, the strains *Msmeg*WT, *Msmeg*pVV16, and *Msmeg*pVV0023 were serially diluted (10-fold) and spotted on the 7H10 agar plates containing increasing concentrations of INH (0, 5, 10, and 15 μg/ml) and ETH (0, 2.5, and 5 μg/ml). The plates were incubated at 37°C for 48 h.

qRT-PCR {#S2.SS8}
-------

Total RNA from *Msmeg*pVV16 (vector control) and *Msmeg*pVV0023 (Rv0023 protein overexpressed) cultures were isolated using Qiagen RNeasy kit. SuperScript III reverse transcriptase (Invitrogen) was used to generate cDNA using random hexamers. Real-time PCR was carried on the BioRad CFX96 system using gene-specific primers ([Table 5](#T5){ref-type="table"}) and EvaGreen qPCR mastermix (Applied Biological Materials Inc.) as per standard protocol. The fold change in expression relative to *Msmeg*pVV16 (vector control) was calculated after normalizing to *sigA*. The 2^−ΔΔ*CT*^ method was used to calculate relative changes in gene expression ([@B24]).

###### 

List of primers used in real-time PCR.

  Primer      Sequence
  ----------- ----------------------
  inhARTFP    GTGAGGGCAACAAGATCGAC
  inhARTRP    GTACGAGTACGCCGAGATGT
  *ndh*RTFP   CGGGTTCAAGACGAAGATCG
  *ndh*RTRP   CTTTCTCGGTGTCCTGCAC
  katGFP      CCAAGTGGGACAACAGCTTC
  katGRP      GAGATCCGAGGTCAGCATCG
  ethAFP      CGCCGAGAAGACCAACAAAT
  ethARP      AATGCTTCTGCACGTCGAAA

NADH/NAD^+^ Cellular Concentration {#S2.SS9}
----------------------------------

To measure the cellular concentration of NADH and NAD^+^, *Msmeg*pVV16 and *Msmeg*pVV0023 cells were grown to an OD~600~ of 0.8--1.2. Cells were collected (1 ml) by centrifugation (11,000 rpm for 2 min). The supernatant was removed and 300 μl of 0.2 M HCl (for NAD^+^ extraction) or 0.2 M NaOH (for NADH extraction) was added to the cells. The cells were resuspended and incubated at 50°C for 10 min after which extracts were cooled to 0°C. The bacterial suspensions were neutralized by adding 0.1 M HCl (for NADH extraction) or 0.1 M NaOH (for NAD^+^ extraction) dropwise while vortexing at high speed. Centrifugation was done to remove the cell debris and supernatant was transferred to a new tube and used immediately. NADH and NAD^+^ concentrations were obtained by spectrophotometrically measuring the rate of MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, 4.2 mM\] (Amresco), reduction by yeast alcohol dehydrogenase II (Sigma Aldrich) in the presence of PES (phenazine ethosulfate, 16.6 mM) (Sigma Aldrich) at 570 nm ([@B23]; [@B37]; [@B42]). The concentration of nucleotide (NADH/NAD^+^) is proportional to the rate of MTT reduction.

Bioinformatics {#S2.SS10}
--------------

Rv0023 protein sequence (UniProt P9WMI3) was used as a query in the SynTax web server^[2](#footnote2){ref-type="fn"}^ for synteny analysis within the *Mycobacteriaceae* family ([@B32]); a conserved domain database search was performed to identify HTH_3 and XRE domains ([@B25]). Orthologous sequences of the *whiB5--Rv0023* intergenic region from different mycobacterial species were retrieved from KEGG genome database and aligned using CLUSTAL OMEGA ([@B39]).

Statistical Analysis {#S2.SS11}
--------------------

Data were presented as mean ± SD. Student's *t-*test and one-way ANOVA were used to determine the statistical significance between groups and values with *p* \< 0.05 were considered to be significant. GraphPad Prism software version 5.02 was used for the statistical analysis.

Results {#S3}
=======

Overexpression of Rv0023 Confers Increased INH and ETH Tolerance in *Msmeg* {#S3.SS1}
---------------------------------------------------------------------------

*Rv0023* is a non-essential gene in *Mtb*, yet it regulates a high number of genes in the genome ([@B38]; [@B35]). *Msmeg* genome does not harbor the ortholog of Rv0023 and hence serves as a good model to study the function of Rv0023. To ascertain the role of *Rv0023*, we constructed an overexpressing strain of Rv0023 in *Msmeg*, *Msmeg*pVV0023. The wild-type *Msmeg*WT, vector control *Msmeg*pVV16, and *Msmeg*pVV0023 strains were subjected to acid fast staining to rule out the effect of vector insertion on cellular integrity. The cells were found to be intact and acid fast ([Supplementary Figure 1](#FS1){ref-type="supplementary-material"}). To further study the role of Rv0023 in cellular physiology, *Msmeg*WT, *Msmeg*pVV16, and *Msmeg*pVV0023 were subjected to different stress conditions as depicted in [Figure 1A](#F1){ref-type="fig"}, and tolerance was measured in terms of CFU. The CFU was counted for all conditions and we observed that overexpression of Rv0023 leads to increased tolerance with regard to INH and ETH, and no effect was observed with any other stress conditions. Tolerance to INH and ETH was not seen either on the wild type or in vector control strains ([Figure 1A](#F1){ref-type="fig"}).

![Survivability of Rv0023 expressing *Msmeg* in stress conditions. **(A)** The *Msmeg*WT, *Msmeg*pVV16, and *Msmeg*pVV0023 were subjected to 0.1% SDS for 6 h, 250 μg of lysozyme for 24 h, 5 mM hydrogen peroxide for 6 h, INH (10 μg/ml), RIF (10 μg/ml), and ETH (5 μg/ml) for 24 h. Cells were plated on 7H10 agar plates and bacterial CFU were counted. Data are presented as the mean ± SD from three biological replicates. **(B)** *Msmeg*pVV16 and *Msmeg*pVV0023 cells were serially diluted and spotted on plates containing increasing concentrations of INH. **(C)** *Msmeg*pVV16 and *Msmeg*pVV0023 cells were serially diluted and spotted on plates containing increasing concentrations of ETH.](fmicb-11-00003-g001){#F1}

The role of Rv0023 in generating tolerant strains was further confirmed via spotting the wild type, vector control, and Rv0023 overexpressed strains in the presence of increasing concentrations of INH and ETH. *Msmeg*WT, *Msmeg*pVV16, and *Msmeg*pVV0023 cells were serially diluted and spotted on plates containing 5, 10, and 15 μg/ml of INH and 2.5 and 5 μg/ml of ETH. Even at higher concentrations, *Msmeg*pVV0023 showed tolerance toward INH and ETH ([Figures 1B,C](#F1){ref-type="fig"} and [Supplementary Figure 2](#FS2){ref-type="supplementary-material"}). The results indicate that Rv0023 expression specifically contributes toward the higher tolerance of INH and ETH in *Msmeg.*

Rv0023 Expression in *Msmeg* Alters the NADH/NAD^+^ Levels {#S3.SS2}
----------------------------------------------------------

Isoniazid and ethionamide are both prodrugs and they are activated by the protein catalase--peroxidase KatG and the NADPH-specific flavin adenine dinucleotide-containing monooxygenase, EthA, respectively. After activation, they react with NAD^+^ to form INH-NAD and ETH-NAD adduct. This species then inhibits the enoyl ACP reductase InhA, which leads to the inhibition of mycolic acid biosynthesis and eventual mycobacterial cell death ([Figure 2A](#F2){ref-type="fig"}). The major common genes to both pathways are the *ndh* (maintains NADH/NAD^+^ ratio) and *inhA*. *Msmeg* orthologs of these and other important genes involved in INH and ETH resistance were subjected to qRT-PCR quantification. Total RNA was isolated from *Msmeg*pVV16 and *Msmeg*pVV0023 and the expression levels compared between the two strains. We found that the expression level of *ndh* (MSMEG_3621) in *Msmeg*pVV0023 was approximately twofold lower than that of *Msmeg*pVV16. No changes in the expression levels were observed in *inhA* (MSMEG_3151), *katG* (MSMEG_6384), and *ethA* (MSMEG_6440) between both strains ([Figure 2B](#F2){ref-type="fig"}). As *ndh* encodes NdhII, which oxidizes NADH to NAD^+^, we reasoned that the ratio of NADH/NAD^+^ might be altered in *Msmeg*pVV0023 strain. So, we measured the cellular ratio of NADH and NAD^+^ in *Msmeg*pVV16 and *Msmeg*pVV0023 strains and found that the ratio of NADH/NAD^+^ is increased in *Msmeg*pVV0023

![*ndh* gene regulation by Rv0023. **(A)** Schematic representation of mechanisms of action of INH and ETH. **(B)** Expression levels of genes involved in INH and ETH resistance pathway in *Msmeg*pVV16 and *Msmeg*pVV0023 cells. Fold change was calculated relative to the vector control pVV16. Data are presented as the mean ± SD from three biological replicates. One-way ANOVA was applied and the *p-*value obtained was *p* \< 0.0001. **(C)** EMSA studies with radiolabeled 300 bp of upstream region of *ndh*. Lane 1: probe without any protein. Lanes 2--4: probe with increasing concentration of purified Rv0023 protein.](fmicb-11-00003-g002){#F2}

([Table 6](#T6){ref-type="table"}). These results indicate that Rv0023 expression alters both the transcript levels of *ndh* gene and NADH/NAD^+^ levels. To find out whether these effects are directly mediated by Rv0023 or through some indirect means, we studied the interaction of recombinant Rv0023 with the upstream region of *ndh* (MSMEG_3261) gene. However, under the experimental conditions mentioned, we did not observe any such positive interaction ([Figure 2C](#F2){ref-type="fig"}).

###### 

Cellular concentration of NADH and NAD^+^.

  Strain           NADH (μM)   NAD^+^ (μM)   NADH/NAD^+^
  ---------------- ----------- ------------- -------------
  MsmegpVV16       8.29        9.93          0.83
  *Msmeg*pVV0023   11.27       9.44          1.19

Rv0023 Negatively Regulates *whiB5* {#S3.SS3}
-----------------------------------

*Rv0023* is in operon with *Rv0024* and is transcribed divergently from *whiB5* ([Figure 3A](#F3){ref-type="fig"}). *Rv0023* and *whiB5* are absent from the non-pathogenic, fast-growing *Msmeg* but are present in *Mtb*. So, we tried to find the co-occurrence of these two genes in other mycobacterial species. Synteny analysis of *Rv0023* and *whiB5* was performed for important species of the *Mycobacterium* genus using the "SynTax" web server ([Figure 3B](#F3){ref-type="fig"}). It was observed that *whiB5* is in synteny with *Rv0023* and that both are present only in pathogenic species of mycobacteria ([Supplementary Table 1](#TS1){ref-type="supplementary-material"}).

![Rv0023 exists in a syntenic relationship with *whiB5* and negatively regulates *whiB5* expression. **(A)** Genomic organization of *whiB5* and *Rv0023* locus. **(B)** Schematic representation showing synteny of *Rv0023* and *whiB5* (within rectangular boxes) from seven mycobacterial species strains. **(C)** β-Galactosidase activity of *whiB5* promoter with ectopic expression of Rv0023 protein and Rv0494 (non-specific protein for negative control). **(D)** β-Galactosidase activity of *Rv0023* promoter in the presence of Rv0023 and Rv0494 overexpression.](fmicb-11-00003-g003){#F3}

The syntenic relationship of the two regulators prompted us to probe the regulation of the *whiB5-Rv0023* locus. To identify the regulatory elements at this locus, upstream regions of *whiB5* and *Rv0023* were cloned in the promoter-less vector pEJ414 and named pEJ*whiB5* and pEJ0023, respectively. The coding region of *Rv0023* was cloned in the pVV16 vector to obtain pVV0023. *Msmeg* was transformed with pEJ*whiB5* or pEJ0023. The strains were again transformed with pVV023 to obtain *Msmeg*pEJ*whiB5*-pVV0023 and *Msmeg*pEJ0023-pVV0023 double transformants. Promoter activities were measured in double transformants (*Msmeg*pEJ*whiB5*-pVV0023, *Msmeg*pEJ*whiB5*-pVV16, *Msmeg*pEJ0023-pVV0023, and *MsmegpEJ0023*-pVV16). Overexpression of Rv0023 caused approximately fivefold decrease in *whiB5* promoter activity ([Figure 3C](#F3){ref-type="fig"}), whereas no significant change in the promoter activity of *Rv0023* was noted ([Figure 3D](#F3){ref-type="fig"}). Rv0494, a FadR transcriptional regulator, was used as a negative control, which did not affect the promoter activities of any of these genes. These data suggest that Rv0023 negatively regulates the expression of *whiB5*, but it is not auto-regulatory.

Rv0023 Binds to *whiB5 in vitro* {#S3.SS4}
--------------------------------

As we have observed that Rv0023 expression represses the promoter activity of *whiB5* in *Msmeg*, it prompted us to further test whether Rv0023 interacts with *whiB5* promoter or not. Five hundred base pairs upstream and 50 bp downstream of *whiB5* gene containing the promoter were radiolabeled and EMSA was performed with the recombinant Rv0023. The radiolabeled upstream region of *whiB5* interacted with the purified recombinant Rv0023 in a dose-dependent manner. No interaction of Rv0023 was observed with non-specific DNA ([Figure 4A](#F4){ref-type="fig"}).

![Rv0023 interaction with *whiB5* upstream. **(A)** Rv0023 binding to *whiB5* upstream in EMSA. Lane 1: radiolabeled *whiB5* upstream with no protein. Lanes 2--7: *whiB5* upstream with increasing concentration of Rv0023 protein. Lane 8: upstream region of Rv0494, a non-specific DNA, with no protein. Lanes 9--10: upstream region of Rv0494, a non-specific DNA, with increasing concentration of Rv0023 protein. **(B)** Six overlapping fragments (F1--F6) covering *whiB5* and *Rv0023* locus. **(C)** EMSA for overlapping fragments of *whiB5* upstream with purified Rv0023 protein. Lanes F1--F6: fragments with (+) and without (--) Rv0023 (8 pmol) protein.](fmicb-11-00003-g004){#F4}

Both EMSA and β-galactosidase assays confirmed that Rv0023 interacts with *whiB5* upstream and negatively regulates *whiB5* expression. In order to find the exact binding site of Rv0023, the 550 bp upstream of *whiB5* was divided into two fragments: UF1 of 340 bp and UF2 of 250 bp ([Figure 4B](#F4){ref-type="fig"}). We observed that only the UF2 fragment binds to Rv0023 ([Supplementary Figure 3](#FS3){ref-type="supplementary-material"}). The UF2 fragment was further divided into six overlapping fragments, F1--F6 ([Figure 4B](#F4){ref-type="fig"} and [Table 7](#T7){ref-type="table"}). Purified Rv0023 binds to fragments F1 and F2, whereas no binding was observed with other fragments ([Figure 4C](#F4){ref-type="fig"}). So, we looked for a binding site at the overlapping region of F1 and F2. We generated new oligonucleotides (OL1--OL5) covering the F1--F2 overlapping region ([Figure 5A](#F5){ref-type="fig"} and [Table 8](#T8){ref-type="table"}). EMSA with these radiolabeled fragments showed that Rv0023 binds to OL1 and OL3 fragments whereas no binding was observed with other fragments ([Figure 5B](#F5){ref-type="fig"}). Close examination of these fragments revealed the presence of an imperfect palindrome present in both sequences, TATAcgtTTTT in OL1 and TATAcgcTTTT in OL3 ([Figure 5C](#F5){ref-type="fig"}). To confirm the binding sites identified, we mutated TATAcgtTTTT to TGTGcgtTGTG in OL1 and TATAcgcTTTT to TGTGcgcTGTG in OL3 to obtain OL1M and OL3M, respectively ([Table 8](#T8){ref-type="table"}). Binding studies have shown that Rv0023 binds to the native OL1 and OL3 fragments, but not to the mutant fragments, OL1M and OL3M ([Figure 5C](#F5){ref-type="fig"}). We conclude that there are two binding sites (TATAcgtTTTT and TATAcgcTTTT) of Rv0023 in the upstream region of *whiB5* comprising an 11-bp imperfect palindromic sequence with a 3-bp spacer region.

###### 

List of overlapping fragments used in [Figure 4](#F4){ref-type="fig"}.

  Overlapping fragment   Sequence
  ---------------------- ---------------------------------------------------------------
  F1                     AGAGCCCGCCACAGACATATACGCTTTTGC CTATGTTTCGTTCAACAAGGAGGCCGGCAC
  F2                     CACCCCTTATGTATATACGTTTTTATCGCG ATTCTCTTGCAGAGCCCGCCACAGACATAT
  F3                     CCATAAGCCGGATACTACCCGGATACGACT CGGCCGCGGCCACCCCTTATGTATATACGT
  F4                     TGGCCGCGCCGGCCGACTCACGGCTCACCG CACGCTCCGGCCATAAGCCGGATACTACCC
  F5                     TCCGCGAGGGACCAGTCACGCGACTCGCGA AGTGCGCGAATGGCCGCGCCGGCCGACTCA
  F6                     GCTCAGGCCCATGGTGCTTACGCCAGTGGC GGCCGCCAGGTCCGCGAGGGACCAGTCACG

###### 

List of overlapping fragments used in [Figure 5](#F5){ref-type="fig"}.

  Overlapping fragment   Sequence
  ---------------------- ------------------------------------------
  OL1                    CACCCCTTATGTATATACGTTTTTATCGCGATTCTCTTGC
  OL2                    TTTTATCGCGATTCTCTTGCAGAGCCCGCCACAGACATAT
  OL3                    AGAGCCCGCCACAGACATATACGCTTTTGCCTATGTTTCG
  OL4                    ACGCTTTTGCCTATGTTTCGTTCAACAAGGAGGCCGGCAC
  OL5                    ATTCTCTTGCAGAGCCCGCCACAGACATATACGCTTTTGC
  OL1M                   CACCCCTTATGTAGAGACGTGTGTATCGCGATTCTCTTGC
  OL3M                   AGAGCCCGCCACAGACAGAGACGCGTGTGCCTATGTTTCG

![Identification of Rv0023 binding site. **(A)** OL1--OL4 spanning the F1--F2 fragments and OL5 comprising the overlapping region of F1--F2. **(B)** EMSA with fragments OL1--OL5 with (+) and without (--) Rv0023 (8 pmol) protein. **(C)** OL1 and OL3 fragments containing the imperfect palindrome, indicated in red. EMSA with mutated imperfect palindromic DNA region. Fragments with (+) and without (--) Rv0023 (8 pmol) protein.](fmicb-11-00003-g005){#F5}

Analysis of Rv0023 Binding Site {#S3.SS5}
-------------------------------

The importance of each residue within the Rv0023 binding site was determined by generating 39 bp probes (M0--M12) containing specific point mutations on each half of the imperfect palindrome and in the spacer region ([Figure 6A](#F6){ref-type="fig"}). The probes were radiolabeled and were used in binding studies with recombinant Rv0023. The binding was observed with probes M0 (unaltered), M1, M4, and M5, and significant loss of binding was observed with M2, M3, M6, M7, and M8 fragments, suggesting the importance of these residues in Rv0023 binding. Changing the residues in the spacer region (M9--M10) did not affect Rv0023 binding; however, changing the length of spacer region by one base lead to significant loss of Rv0023 binding (M11--M12) ([Figure 6B](#F6){ref-type="fig"}). As mentioned earlier, the organization of *Rv0023* and *whiB5* is conserved across pathogenic mycobacterial species. Therefore, we looked into the conservation of identified Rv0023 binding sites across the conserved genomes. For this, we aligned the upstream region of *whiB5* orthologs from different pathogenic mycobacterial species strains and found that the two binding sites of Rv0023 are conserved across the analyzed mycobacterial species ([Figure 6C](#F6){ref-type="fig"}). These results highlight the important residues for Rv0023 binding and its conservation across mycobacterial species.

![Identification of important residues in the imperfect palindrome for Rv0023 binding. **(A)** Representation of probes (∼40 bp each) containing native binding site M0 and probe with mutation at specific positions in the binding site M1--M8 and probe with mutation in spacer regions M9--M12. **(B)** EMSA with radiolabeled probes \[native (M0), mutated (M1--M9), and altered (M9--M12)\] with constant concentration of purified Rv0023 protein. Fragments with (+) and without (--) Rv0023 (8 pmol) protein. **(C)** Multiple sequence alignment of *whiB5* upstream from selected members of mycobacterial species. The two binding sites of Rv0023 are highlighted in rectangular boxes.](fmicb-11-00003-g006){#F6}

Rv0023 Binding Site Overlaps With the *whiB5* Promoter Region {#S3.SS6}
-------------------------------------------------------------

In order to understand the mechanism of Rv0023-mediated repression of *whiB5*, the TSSs of *whiB5* and *Rv0023* were mapped. The putative −10 region of *whiB5* was identified earlier by RACE ([@B9]) ([Figure 7A](#F7){ref-type="fig"}). To test the functionality of the putative −10 region, we cloned the 250 bp upstream of *whiB5* into lacZ reporter vector (pEJ*whiB5*WT). The promoter activity was measured using the β-galactosidase assay in *Msmeg*. Mutations in the putative −10 region of *whiB5* (atacgctt to gcacgcgg) abolished the promoter activity, confirming the −10 region of *whiB5* ([Figure 7B](#F7){ref-type="fig"}). To identify the promoter region of *Rv0023*, primer extension was performed. We identified the TSS at 228 bp upstream of *Rv0023* start codon ([Figure 7C](#F7){ref-type="fig"}). A −10-like hexamer sequence TCATAG was identified upstream of TSS. To validate the functionality of the −10 region of *Rv0023*, 400 bp upstream of Rv0023 was cloned into a lacZ reporter vector (pEJ0023WT). β-Galactosidase assay with WT promoter and mutated promoter (pEJ0023MUT) indicated significant decrease in the promoter activity of the mutant strain compared to WT ([Figure 7D](#F7){ref-type="fig"}). Mapping the promoters of *whiB5* and *Rv0023* with Rv0023 binding site revealed that Rv0023 binding site overlaps with the promoter of *whiB5* but not of the *Rv0023* promoter region ([Figure 7E](#F7){ref-type="fig"}).

![Identification of promoter regions of *whiB5* and *Rv0023*. **(A)** Nucleotide sequence of *whiB5* upstream containing *whiB5* start codon and --10 region. The --10 region is highlighted in bold. **(B)** β-Galactosidase activity of *Msmeg* transformed with *whiB5* wild-type promoter (pEJ*whiB5*WT), *whiB5* mutated (pEJ*whiB5*MUT) promoter, and vector control. **(C)** Primer extension analysis of *Rv0023*. PE1 and PE2 indicate two primers used for primer extension assay. The primer extension product is indicated by an arrow. G, A, T, and C indicate the sequencing ladder generated by using dideoxy nucleotides. **(D)** β-Galactosidase activity of predicted *Rv0023* wild type (pEJ0023WT) and *Rv0023* mutated (pEJ0023MUT) promoter showing significantly reduced activity of mutated promoter. **(E)** Genomic organization of Rv0023 binding sites (shown in bold and colored) and promoter regions (bold and boxed) of *whiB5* and *Rv0023*. Start codons are represented by an arrow.](fmicb-11-00003-g007){#F7}

Discussion {#S4}
==========

In this study, Rv0023, a member of the XRE family of transcriptional regulators, has been characterized, and its role in INH and ETH drug tolerance has been explored. The first part of our study concerns the role of Rv0023 in the physiology of mycobacteria. For our study, we used *Msmeg* as a surrogate model to study the effects of various stress conditions on wild type and Rv0023-expressing strains. It was observed that overexpression of Rv0023 confers higher tolerance toward INH and ETH in *Msmeg*. It was seen that the ectopic expression of Rv0023 alters the NADH/NAD^+^ ratio, thereby increasing drug tolerance. In the second part of the manuscript, we identified Rv0023 as a transcriptional regulator and studied the regulatory effect at *whiB5-Rv0023* locus and observed that Rv0023 negatively regulates *whiB5* expression but is not auto-regulatory. Rv0023 regulates *whiB5* expression by binding to specific sequences in the upstream region of *whiB5*. Our data indicate that there are two binding sites for Rv0023 upstream of *whiB5* and one of the sites overlaps with the *whiB5* promoter, thereby possibly occluding the binding of RNA polymerase. The binding site of Rv0023 is conserved across mycobacterial species as confirmed by multiple sequence alignment. Apart from this, we have also characterized the binding site of Rv0023 and found important bases for binding. While analyzing the spacer region, it was found that the length of the spacer region is important for proper binding.

Isoniazid, isonicotinic acid hydrazide, is a synthetic drug and the occurrence of INH-resistant strains is significantly more frequent than other drug-resistant *Mtb* clinical strains ([@B30]). ETH, 2-ethylthioisonicotinamide, is a structural analog of INH and was first synthesized in 1956 ([@B15]). Many genes have been found to be associated with INH and ETH resistance in clinical isolates, but the role of transcription factors regulating INH and ETH co-resistance is poorly understood. Rv0023, a transcriptional regulator, conferring higher tolerance toward INH and ETH in *Msmeg*, provided us a chance to explore the role of transcription factors in INH and ETH co-resistance in *Mtb*. To elucidate the mechanism by which Rv0023 confers drug tolerance, we investigated two main genes known to be involved in INH and ETH co-resistance, *inhA* (enzyme involved in the synthesis of cell wall mycolic acid) ([@B2]) and *ndh* (NADH dehydrogenase maintains the NADH/NAD + ratio) ([@B28]). We checked their expression levels in the vector control and Rv0023-expressing *Msmeg* strains and differential expression was only observed in the *ndh* gene. The *ndh* gene oxidizes NADH to NAD^+^, which maintains the ratio of NADH/NAD^+^ in mycobacterial cells ([@B17]). Loss of *ndh* function leads to higher levels of NADH in the cytosol. Previous studies have shown that the higher NADH/NAD^+^ levels interfere with activation of INH/ETH drugs by competitive inhibition with the formation of INH-NAD and ETH-NAD and thus confer resistance to INH/ETH in *Msmeg* and BCG ([@B28]; [@B42]). So, we further measured the NADH/NAD^+^ ratio in vector control and Rv0023-expressing *Msmeg* strains. The NADH/NAD^+^ ratio was found to be increased in the Rv0023-overexpressed *Msmeg* strain, suggesting that negative regulation of *ndh* gene by Rv0023 is probably the mechanism by which Rv0023 confers INH and ETH tolerance in *Msmeg*. Our results were supported by previous studies where it was shown that Rv0023 regulon is enriched for NAD reductases ([@B35]). Rv0023 did not bind to the upstream region of ndh, indicating that the regulation occurs possibly through indirect means, which may involve multiple intermediate gene products. Further studies are required to completely decipher this mechanism.

Synteny analysis has shown that *whiB5-Rv0023* locus is present mainly in pathogenic species of mycobacteria. The gene *whiB5* belongs to the WhiB family of transcriptional regulators, which are exclusive to actinomycetes, such as *Mycobacterium* and *Streptomyces* spp. ([@B40]). Earlier studies have shown that *whiB5* is a global transcriptional regulator, regulating 58 genes of diverse functions, including *sigM* and genes encoding for Type VII secretion systems such as *esx-2* and *esx-4*. It was shown that *whiB5* has a role in *Mtb* virulence and reactivation ([@B9]). As the whole locus of *whiB5-Rv0023*-*Rv0024* is absent in *Msmeg*, it is difficult to gauge the true effect of Rv0023 in the physiology of *Mtb*. Further investigation in *Mtb* may reveal important aspects of Rv0023 regulation and its effects. Hence, taking into account the earlier studies and our current data, we surmise that Rv0023 plays a significant role in modulating genes associated with NADH/NAD^+^ levels, which further influences mycobacterial physiology.

In conclusion, our work shows, for the first time, that Rv0023 has a role in conferring INH and ETH tolerance in *Msmeg*. Understanding the role of transcriptional factors in the development of drug resistance will open new avenues in the field of drug discovery and may provide important insights into *Mtb* physiology.
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